Yazar "Batur, Osman" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Yayın
    Bir olgu nedeniyle gebelik kolestazı, fetal riskler ve ursodeoksikolik asit tedavisi
    (Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, 2005) Tüfekçi, Ertuğrul Can; Batur, Osman; Temelli, Figen
    Bu yazıda amacımız gebelik kolestazını incelemektir. Burada 36 yaşında gebelik kolestazı tanısı almış bir kadın hastayı sunduk. Gebelik kolestazı, nedeni tam olarak bilinmeyen, maternal kaşıntı ve ikter gibi semptomlarla karşımıza çıkan nadir görülen bir hastalıktır. Hastalık belirgin maternal risk taşımazken, perinatal mortalite, preterm doğum, fetal distress ve mekonyum boyanması gibi ciddi fetal risklerle beraberdir. Yazımızda hastalığın epidemiolojisi, patomekanizması ve tedavisini tartıştık. Ursodeoksikolik asit tedavisi ile komplet bir kür sağlandı. Literatür bilgileri ve kendi tecrübelerimiz ışığında gebelik kolestazı tedavisinde ursodeoksikolik asit’i önermekteyiz.
  • Küçük Resim Yok
    Yayın
    Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis
    (Taylor and Francis Online, 2006) Karalok, Hakan; Tüfekçi, E. C.; Batur, Osman
    Objective Risedronate is a bisphosphonate used in the treatment of osteoporosis. It has a strong effect in inhibiting osteoclast activity. The primary objective of this study was to evaluate the effectiveness and adverse events of two different forms of risedronate (5 mg and 35 mg) using a rapid biochemical marker for comparison of C-terminal telopeptide (CTx) type I collagen cross-links. Methods The study was designed at Bakırkoy Dr. Sadi Konuk Education & Research Hospital, between January and June 2004. A total of 123 postmenopausal osteoporotic women were randomly assigned in blocks of three to one of the following groups: control, risedronate 5 mg/day and risedronate 35 mg once a week. Results Of the 123 women enrolled, 103 (83.7%) completed the study. Adverse events were experienced by 53.6% in the control group, 56% in the risedronate 5 mg/day group and 53.6% in the group receiving risedronate 35 mg once per week. The most common adverse events were gastrointestinal (21.9% of subjects in group 1, 29.2% of subjects in group 2, 24.3% of subjects in group 3). The women in groups receiving risedronate either 5 mg/day and 35 mg once per week had similarly decreased levels of CTx but the control group was not as effective. Conclusion The results support the hypothesis that risedronate 35 mg given once per week has the same therapeutic efficacy and safety as a daily 5 mg regimen. Taking the medicine once a week is likely to be easier and more satisfactory than the daily regimen. However, patients taking a once-a-week regimen may forget to take it due to the 7-day break without medicine.
  • Küçük Resim Yok
    Yayın
    Unruptured cornual (interstitial) pregnancy: a case report
    (Türkiye Klinikleri, 2005) Karalök, Hakan; Tüfekçi, Ertuğrul Can; Akyol, Hürkan; Batur, Osman
    A case report of cornual pregnancy is presented. A 28 years old woman, gravida 3 para 2 was admitted to the hospital with abdominal pain and vaginal bleeding with suspicion of ectopic pregnancy. After the preoperative diagnosis of ectopic pregnancy, cornual resection was performed by laparotomy. Histological studies confirmed cornual pregnancy. The patient had only history of intrauterine device usage and pelvic inflamatuar disease as risk factors.